USRE34069E - Process for the preparation of oligonucleotides - Google Patents

Process for the preparation of oligonucleotides Download PDF

Info

Publication number
USRE34069E
USRE34069E US07/481,572 US48157290A USRE34069E US RE34069 E USRE34069 E US RE34069E US 48157290 A US48157290 A US 48157290A US RE34069 E USRE34069 E US RE34069E
Authority
US
United States
Prior art keywords
nucleoside
protected
carrier
group
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/481,572
Inventor
Hubert Koster
Nanda D. Sinha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proligo LLC
Original Assignee
BIOSYNTECH Biochemische Synthesetechnik GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19833329892 external-priority patent/DE3329892A1/en
Application filed by BIOSYNTECH Biochemische Synthesetechnik GmbH and Co filed Critical BIOSYNTECH Biochemische Synthesetechnik GmbH and Co
Priority to US07/481,572 priority Critical patent/USRE34069E/en
Application granted granted Critical
Publication of USRE34069E publication Critical patent/USRE34069E/en
Assigned to MILLIPORE CORPORATION reassignment MILLIPORE CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BIOSYNTECH GMBH
Assigned to MILLIPORE INVESTMENT HOLDINGS LTD. reassignment MILLIPORE INVESTMENT HOLDINGS LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MILLIPORE CORPORATION
Assigned to PERSEPTIVE BIOSYSTEMS, INC. reassignment PERSEPTIVE BIOSYSTEMS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MILLIPORE INVESTMENT HOLDINGS LIMITED
Assigned to NEXSTAR PHARMACEUTICALS, INC. reassignment NEXSTAR PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PERSEPTIVE BIOSYSTEMS, INC.
Assigned to PROLIGO L.L.C. reassignment PROLIGO L.L.C. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEXSTAR PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • the invention relates to a process for the preparation of oligonucleotides of the general formula I indicated in claim 1.
  • the oligonucleotides prepared according to the invention have defined sequences and can be used as specific primers and probes and are of great importance for the synthesis of complete genes (Arzneistoffforschung 30, 3a, 548, (1980)).
  • oligonucleotides are prepared by either the phosphate or phosphite triester method using polymeric carriers (Nachr. Chem. Tech. Lab. 29, 230 (1981)). In order to be able to construct defined sequences, it is necessary for the individual units (nucleoside or nucleotides) to be provided with suitable protective groups.
  • base-labile acyl groups are generally used for the protection of the exocyclic amino groups on the heterocyclic nucleobases, and a base-labile ester bond is used to attach the oligonucleotide chain to the polymeric carrier in a customary manner, and acid-labile trityl ether groups are used to protect the primary 5'--OH group.
  • the phosphate protective group used in the phosphate triester method is customarily either the 2-chlorophenyl or the 4-chlorophenyl group, with an ester-type bond, which can only be removed by attack of a base or a nucleophile on the phosphorus atom.
  • the methyl group with an ester-type bond is customarily used as the phosphate protective group which can be removed by attack of a nucleophile on the methyl C atom (J. Amer. Chem. Soc. 99, 3526 (I1977)). Since attack on the P atom is avoided, there is likewise avoidance of the risk of cleavage of the internucleotide bond.
  • the nucleophile customarily used is thiophenol/triethylamine, which are unpleasant to manipulate and, moreover, lead to involatile compounds which are difficult to extract and which, as mentioned above, both make work-up difficult and lead to considerable material losses.
  • B denotes a nucleobase, for example adenine (A), guanine (G), cytosine (C), thymine (T) or uracil (U) or their analogs
  • R 1 denotes hydrogen, hydroxyl or hydroxyl which is protected by the protective groups customary in nucleotide chemistry
  • n denotes an integer from 1 to 200
  • R 1 of the general formula II can be hydrogen; in this case the compounds of the formula I are oligodeoxynucleotides.
  • the group R 1 can also be hydroxyl or hydroxyl which is, where appropriate, protected by the protective groups customary in nucleotide chemistry.
  • protective groups of this type are trityl, monomethoxytrityl and dimethoxytrityl, acyl, for example acetyl, benzoyl; tetrahydropyranyl, methoxytetrahydropyranyl, o-nitrobenzyl and silyl ethers, such as, for example, t-butyldiphenylsilyl ethers.
  • R 2 is likewise a protective group customary in nucleotide chemistry according to the above mentioned publications, preferably the acid-labile 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytrityl group.
  • B' can likewise have a protective group customary in nucleotide chemistry according to the above mentioned prior publications.
  • X denotes chlorine, bromine, CN or SCN
  • L denotes chlorine, bromine, CN, SCN or an amino radical of the formula--NR 2 4 (formula VIII), where the groups R 4 denote primary, or secondary or tertiary alkyl radicals having 1-10 carbon atoms, or together denote a cycloalkyl radical having 5-7 carbon atoms, optionally with alkyl branches, and/or can contain one or two nitrogen, oxygen and/or sulfur atoms as heteroatoms.
  • the group L can also form a reactive heterocyclic radical, the imidazolyl, triazolyl, tetrazolyl, 3-nitro-1,2,4-triazolyl, thiazolyl, pyrrolyl, benzotriazolyl (optionally with substituents in the phenyl moiety) or benzohydroxytriazolyl (optionally with substituents in the phenyl ring) and the like.
  • R 3 is the phosphine derivative of the general formula (III) is, according to the invention, a group of the general formula VII, ##STR5## which can be removed with the aid of bases by ⁇ -elimination and in which Y denotes hydrogen, methyl or ethyl.
  • Z represents an electron-attracting group, for example, halogen, such as fluorine, chlorine or bromine, CN or NO 2 .
  • Z can also denote phenyl, phenylthio, phenylsulfoxy or phenylsulfonyl, it being possible for the phenyl radicals to be substituted in the o,o'-position and/or p-position with halogen, CN or NO 2 . It is also possible for one of the groups CF 3 , CCl 3 or CBr 3 to replace the group ##STR6##
  • step a takes place in the presence of an organic base.
  • the reaction of the compound according to formula IV is carried out with a nucleoside of the general formula V according to claim 1, which is bound to a polymeric carrier.
  • soluble or insoluble, that is to say crosslinked, polymeric carriers for example modified silica gel, glass, especially "controlled pore glass", polyester, polyamide, polyvinyl alcohol, polysiloxane, polystyrene or the like.
  • Ester bonds are suitable and preferred for the attachment between the carrier and the nucleoside, including those derived from the levulinyl or ⁇ -benzoylpropionyl radical; the latter ester bonds can be cleaved with hydrazine under neutral conditions.
  • the acid-labile trityl ether bond optionally with substituents in the phenyl rings, is also suitable as a method of attachment, compare Liebigs Ann. Chem. 1974, 959.
  • the elimination is carried out using, for example, a protonic acid or Lewis acid, such as ZnBr 2 or dialkylaltuminum chloride, when R 2 represents a trityl group or a methoxy derivative thereof.
  • a protonic acid or Lewis acid such as ZnBr 2 or dialkylaltuminum chloride
  • Steps a-e can be repeated to introduce at least one nucleoside phosphate moiety.
  • the chains are lengthened by more than one nucleoside phosphate unit.
  • This elimination can be carried out in such a manner that, using aqueous ammonia, in one step the N-acyl groups on the heterocyclic bases, the ester bond between the oligonucleotide and the carrier (the latter can, where appropriate, also be cleaved with hydrazine under neutral conditions) an the phosphate protective group are eliminated by ⁇ -elimination in accordance with the general scheme 1 at the end of the description.
  • An oligonucleotide having only a 5'-terminal trityl protective group is then obtained, and this can be purified directly in a manner known per se, after removal of the volatile base (ammonia), by high-pressure liquid chromatography (HPLC) on reverse phase material.
  • the intermediates of the general formula IV according to claim 1 are new compounds. They are in the form of very stable compounds which can be prepared in the pure form and are easy to manipulate but nevertheless are very reactive in the sense of forming internucleotide bonds.
  • R 3 as a protective group which can be removed by bases via ⁇ -elimination makes is possible for the first time to eliminate all the protective groups, apart from the 5'-trityl group, in one step where, in an advantageous manner, by the use of volatile bases the desired oligonucleotide is contaminated with foreign materials to only a very small extent and thus directly afterwards can be purified by reverse phase HPLC due to the hydrophobic 5'-trityl group which is still present.
  • a further advantage of the process of the invention results from the fact that, due to the removal of the protective group by ⁇ -elimination, no attack on the P-atom takes place and thus none of the newly formed internucleotide bonds can be cleaved during the deprotection.
  • the process of the invention takes very much less time and leads to overall purer products than do the processes hitherto available.
  • dichloro- ⁇ -cyanoethoxyphosphine (1) is prepared as in Can. J. Chem. 58, 2686 (1980):
  • FIGS. 1a, 1b and 1c show 31 P NMR spectra of three different ⁇ -cyanoethyl phosphoramidochloridites.
  • the N-morpholine derivative is too unstable to heat for distillation to be possible. Nevertheless, the preparation is so pure that the residue can be used directly for the preparation of the activated nucleoside derivatives. The purity is usually greater than 95% according to the 31 P NMR spectra.
  • the amine hydrochloride is filtered off under argon and thoroughly washed with dry THF (10 to 15 ml).
  • the entire organic phase is concentrated and dissolved in argon-saturated ethyl acetate (100 ml).
  • the organic phase is extracted twice with 50 ml each time of argon-saturated 10% aqueous sodium carbonate solution.
  • the organic phases are dried with sodium sulfate and evaporated under reduced pressure to give a foam.
  • the foam is dissolved in a little ethyl acetate or toluene and precipitated in n-hexane at -78° C.
  • the activated nucleosides are stable for several months when stored at -20° C. under argon.
  • FIG. 2 shows the 31 P NMR spectrum of one of the activated deoxynucleosides.
  • the overall yield of the protected octanucleotide at the end of all condensation steps is 55% based on carrier-bound deoxyguanosine.
  • the fractions which contain the 5'-dimethoxytritylated oligonucleotide are collected; the volatile buffer is removed in a rotary evaporator in vacuo, 1 ml of 80% strength acetic acid is added to the residue. After 45 minutes at room temperature, the acetic acid is removed by freeze-drying.
  • the material thus obtained is phosphorylated in the customary manner (Liebigs Ann. Chem. 1978, 982) with T4-polynucleotide kinase and ⁇ - 32 P-ATP.
  • the resulting product is characterized by polyacrylamide gel electrophoresis comparing with a homo-oligo-dT chain length standard (Nucleic Acids Res. 6, 2096 (1979), FIG. 4) and by sequencing according to FIG. 5 (Liebigs Ann. Chem. 1978, 982).
  • FIGS. 6a to 6c show the results (HPLC, gel electrophoresis, sequencing) of the synthesis of d(GGGATCCC) using the nucleoside ⁇ -cyanoethyl N,N-dimethylphosphoramidites
  • FIGS. 6a to 6c show the results (HPLC, g, electrophoresis, sequencing) of the synthesis of d(GGGATATCCC) using the nucleoside ⁇ -cyanoethyl N,N-morpholinophosphoramidites.

Abstract

The invention relates to a process for the preparation of oligonucleotides by the following steps: reaction of a nucleoside with a phosphine derivative, reaction of the nucleotide derivative thus obtained with a nucleoside bonded to a polymeric carrier, oxidation of the carrier-bound nucleoside-nucleotide thus obtained with formation of phosphotriester groups, blocking of free primary 5'--OH groups, elimination of a protective group from the terminal 5'--OH group, where appropriate single or multiple repetition of the abovementioned steps to introduce further nucleoside phosphate or oligonucleoside phosphate units, and cleavage of the nucleoside-carrier bond and, where appropriate, elimination of all protective groups present in the oligonucleoside phosphates. The phosphine derivative used is a compound of the general formula III ##STR1## in which X and L can react with OH groups of the sugar units in the oligonucleotides, and R3 is a protective group which can be liberated by β-elimination.

Description

DESCRIPTION
The invention relates to a process for the preparation of oligonucleotides of the general formula I indicated in claim 1. The oligonucleotides prepared according to the invention have defined sequences and can be used as specific primers and probes and are of great importance for the synthesis of complete genes (Arzneimittelforschung 30, 3a, 548, (1980)).
According to the most recent state of the art, oligonucleotides are prepared by either the phosphate or phosphite triester method using polymeric carriers (Nachr. Chem. Tech. Lab. 29, 230 (1981)). In order to be able to construct defined sequences, it is necessary for the individual units (nucleoside or nucleotides) to be provided with suitable protective groups. In this context, base-labile acyl groups are generally used for the protection of the exocyclic amino groups on the heterocyclic nucleobases, and a base-labile ester bond is used to attach the oligonucleotide chain to the polymeric carrier in a customary manner, and acid-labile trityl ether groups are used to protect the primary 5'--OH group. The phosphate protective group used in the phosphate triester method is customarily either the 2-chlorophenyl or the 4-chlorophenyl group, with an ester-type bond, which can only be removed by attack of a base or a nucleophile on the phosphorus atom. This type of step is inherently undesirable since it involves the risk of cleavage of the internucleotide phosphate ester bond. This risk has been greatly reduced by the use of oximate anions (Tetrahedron Lett. 19, 2727 (1978)), although these also attack the phosphorus atom in an undesired manner in the crucial step and, moreover, have the disadvantage that a relatively small amount of desired oligonucleotide is contaminated with every large amounts of involatile salts which are difficult to extract. This not only makes the working up and subsequent purification of the synthesized oligonucleotide difficult but also leads to considerable material losses.
In the phosphite triester method, the methyl group with an ester-type bond is customarily used as the phosphate protective group which can be removed by attack of a nucleophile on the methyl C atom (J. Amer. Chem. Soc. 99, 3526 (I1977)). Since attack on the P atom is avoided, there is likewise avoidance of the risk of cleavage of the internucleotide bond. The nucleophile customarily used is thiophenol/triethylamine, which are unpleasant to manipulate and, moreover, lead to involatile compounds which are difficult to extract and which, as mentioned above, both make work-up difficult and lead to considerable material losses.
Although the actual synthesis of oligonucleotides by the solid phase/phosphite or phosphate triester method takes place very efficiently and rapidly, the preparation of oligonucleotides of defined sequence remains very time-consuming. This is primarily due to the problems of the subsequent work-up and purification which take up a multiple of the actual synthesis time. The process of the invention operates at this point and provides in this connection a crucial technical improvement.
In order to obtain compounds of the formula I indicated in claim 1, ##STR2## in which B denotes a nucleobase, for example adenine (A), guanine (G), cytosine (C), thymine (T) or uracil (U) or their analogs, and R1 denotes hydrogen, hydroxyl or hydroxyl which is protected by the protective groups customary in nucleotide chemistry, and n denotes an integer from 1 to 200, according to the invention a variety of defined reaction steps are carried out, as follows:
(a) Reaction of a nucleoside of the general formula II. ##STR3##
R1 of the general formula II can be hydrogen; in this case the compounds of the formula I are oligodeoxynucleotides. The group R1 can also be hydroxyl or hydroxyl which is, where appropriate, protected by the protective groups customary in nucleotide chemistry. Examples of protective groups of this type are trityl, monomethoxytrityl and dimethoxytrityl, acyl, for example acetyl, benzoyl; tetrahydropyranyl, methoxytetrahydropyranyl, o-nitrobenzyl and silyl ethers, such as, for example, t-butyldiphenylsilyl ethers. A general review of the protective groups customary in nucleotide chemistry is to be found in, for example, Tetrahedron 1981, pages 363-369, Liebigs Ann. Chem. 1978, 839-850, and Nucleic Acids Research, Symposium Series No. 7, 1980, 39-59.
R2 is likewise a protective group customary in nucleotide chemistry according to the above mentioned publications, preferably the acid-labile 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytrityl group. B' can likewise have a protective group customary in nucleotide chemistry according to the above mentioned prior publications.
The nucleoside of the formula II is reacted according to the invention with a phosphine derivative of the general formula III according to claim 1. ##STR4##
In the general formula, X denotes chlorine, bromine, CN or SCN; L denotes chlorine, bromine, CN, SCN or an amino radical of the formula--NR2 4 (formula VIII), where the groups R4 denote primary, or secondary or tertiary alkyl radicals having 1-10 carbon atoms, or together denote a cycloalkyl radical having 5-7 carbon atoms, optionally with alkyl branches, and/or can contain one or two nitrogen, oxygen and/or sulfur atoms as heteroatoms. The group L can also form a reactive heterocyclic radical, the imidazolyl, triazolyl, tetrazolyl, 3-nitro-1,2,4-triazolyl, thiazolyl, pyrrolyl, benzotriazolyl (optionally with substituents in the phenyl moiety) or benzohydroxytriazolyl (optionally with substituents in the phenyl ring) and the like.
R3 is the phosphine derivative of the general formula (III) is, according to the invention, a group of the general formula VII, ##STR5## which can be removed with the aid of bases by β-elimination and in which Y denotes hydrogen, methyl or ethyl. Z represents an electron-attracting group, for example, halogen, such as fluorine, chlorine or bromine, CN or NO2. Z can also denote phenyl, phenylthio, phenylsulfoxy or phenylsulfonyl, it being possible for the phenyl radicals to be substituted in the o,o'-position and/or p-position with halogen, CN or NO2. It is also possible for one of the groups CF3, CCl3 or CBr3 to replace the group ##STR6##
The reaction according to step a takes place in the presence of an organic base.
(b) Reaction of the nucleoside-.[.phosphorous.]. .Iadd.phosphorus .Iaddend.acid derivative, of the formula IV, obtained in step a. ##STR7##
The reaction of the compound according to formula IV is carried out with a nucleoside of the general formula V according to claim 1, which is bound to a polymeric carrier. ##STR8## It is possible to use soluble or insoluble, that is to say crosslinked, polymeric carriers, for example modified silica gel, glass, especially "controlled pore glass", polyester, polyamide, polyvinyl alcohol, polysiloxane, polystyrene or the like. Ester bonds are suitable and preferred for the attachment between the carrier and the nucleoside, including those derived from the levulinyl or β-benzoylpropionyl radical; the latter ester bonds can be cleaved with hydrazine under neutral conditions. The acid-labile trityl ether bond, optionally with substituents in the phenyl rings, is also suitable as a method of attachment, compare Liebigs Ann. Chem. 1974, 959.
(c) Oxidation of the carrier-bond nucleotide-nucleoside, of the general formula VI, obtained in step b. ##STR9##
Oxidation leads to a phosphate group; this can be carried out with, for example, iodine/H2 O, H2 O2 or organic peracids or, in general, by oxidation by introduction of O, S or Se.
(d) Blocking of free primary 5'--OH groups which have not been reacted in the reaction according to step b (in the product of the formula V).
These free hydroxyl groups are blocked with a permanent protective group, for example by reaction with acetic anhydride.
(e) Elimination of the protective groups(s) R2.
The elimination is carried out using, for example, a protonic acid or Lewis acid, such as ZnBr2 or dialkylaltuminum chloride, when R2 represents a trityl group or a methoxy derivative thereof.
(f) Introduction of further nucleoside phosphate or oligonucleoside phosphate units.
Steps a-e can be repeated to introduce at least one nucleoside phosphate moiety. Of course, when oligonucleoside phosphate units are employed, the chains are lengthened by more than one nucleoside phosphate unit.
(g) Elimination of all protective groups.
This elimination can be carried out in such a manner that, using aqueous ammonia, in one step the N-acyl groups on the heterocyclic bases, the ester bond between the oligonucleotide and the carrier (the latter can, where appropriate, also be cleaved with hydrazine under neutral conditions) an the phosphate protective group are eliminated by β-elimination in accordance with the general scheme 1 at the end of the description. An oligonucleotide having only a 5'-terminal trityl protective group is then obtained, and this can be purified directly in a manner known per se, after removal of the volatile base (ammonia), by high-pressure liquid chromatography (HPLC) on reverse phase material.
The intermediates of the general formula IV according to claim 1 are new compounds. They are in the form of very stable compounds which can be prepared in the pure form and are easy to manipulate but nevertheless are very reactive in the sense of forming internucleotide bonds. The use of R3 as a protective group which can be removed by bases via β-elimination makes is possible for the first time to eliminate all the protective groups, apart from the 5'-trityl group, in one step where, in an advantageous manner, by the use of volatile bases the desired oligonucleotide is contaminated with foreign materials to only a very small extent and thus directly afterwards can be purified by reverse phase HPLC due to the hydrophobic 5'-trityl group which is still present.
A further advantage of the process of the invention results from the fact that, due to the removal of the protective group by β-elimination, no attack on the P-atom takes place and thus none of the newly formed internucleotide bonds can be cleaved during the deprotection. Thus, the process of the invention takes very much less time and leads to overall purer products than do the processes hitherto available.
The invention is illustrated in detail below by means of examples, the phosphine derivatives used being those in which R3 is a β-cyanoethyl group. Details of the reaction and physical characteristics of the compounds prepared can be seen in schemes 2 and 3, Table 1, and FIGS. 1-7 at the end of the description.
EXAMPLE 1 Preparation of phosphine derivatives of the general formula III:
β-Cyanoethyl phosphoramidochloridite:
A general summary of the reaction can be seen in scheme 2.
Apart from some improvements, dichloro-β-cyanoethoxyphosphine (1) is prepared as in Can. J. Chem. 58, 2686 (1980):
300 ml of ether and 79.0 g (1 mol) of pyridine are added through a dropping funnel to 137.5 g (1.0 mol) of PCl3 in a three-neck flask; the mixture is cooled to -78° C. under argon. Then a solution of 71.0 g (1 mol) of β-cyanoethanol in 150 ml of dry ether is added dropwise over the course of 1 to 1.5 hours. The cooling bath is removed; stirring is continued at room temperature for a further 3 hours (where necessary, another 300 ml of ether are added in order to ensure better stirrability). The stirrer and dropping funnel are removed under argon; the mixture is stored at 0° C. overnight. The solid salts are removed under argon; the precipitate is washed twice with 75 ml of ether each time. The combined organic phases are concentrated in vacuo; the residue is finally distilled in vacuo; boiling point 70°-75° C./0.4 mm Hg.
β-Cyanoethyl phosphoramidochloridite (3):
A solution of 17.2 g (0.1 mol) of β-cyanoethyl phosphorodichloridite (1) in 60 ml of ether is added dropwise, over the course of 1 to 1.5 hours, to a solution of the N-trimethylsilylated secondary amine (0.1 mol) or secondary amine (0.2 mol) in 30 ml of ether at -20° C. under argon. After stirring at room temperature for 20 hours, the amine hydrochloride is removed; the remaining solution is concentrated. The residue is finally distilled in vacuo in a short-path distillation apparatus.
The physical properties of the compounds thus obtained are summarized in Table 1.
FIGS. 1a, 1b and 1c show 31 P NMR spectra of three different β-cyanoethyl phosphoramidochloridites.
The N-morpholine derivative is too unstable to heat for distillation to be possible. Nevertheless, the preparation is so pure that the residue can be used directly for the preparation of the activated nucleoside derivatives. The purity is usually greater than 95% according to the 31 P NMR spectra.
Nucleoside β-cyanoethyl phosphoramidites:
The preparation of the appropriately protected nucleoside β-cyanoethyl phosphoramidites can be seen in scheme 3.
The synthesis is analogy to Tetrahedron Lett. 22, 1859 (1981), with some improvements, provides good yields.
3.0 mmol of the N-protected 5'-dimethoxytritylated deoxynucleoside are dried azeotropically using THF/toluene, dissolved in 15 ml of dry THF, and 12.0 mmol of N,N,N-diisopropylethylamine are added. 6.0 mmol of the β-cyanoethyl phosphoramidochloridite are added dropwise to the solution under argon, with vigorous stirring, over the course of 2 minutes. After a short time (2 to 5 minutes), the amine hydrochloride precipitates out. The suspension is stirred for a further 30 to 40 minutes. The amine hydrochloride is filtered off under argon and thoroughly washed with dry THF (10 to 15 ml). The entire organic phase is concentrated and dissolved in argon-saturated ethyl acetate (100 ml). The organic phase is extracted twice with 50 ml each time of argon-saturated 10% aqueous sodium carbonate solution. The organic phases are dried with sodium sulfate and evaporated under reduced pressure to give a foam. The foam is dissolved in a little ethyl acetate or toluene and precipitated in n-hexane at -78° C. The activated nucleosides are stable for several months when stored at -20° C. under argon.
FIG. 2 shows the 31 P NMR spectrum of one of the activated deoxynucleosides.
Synthesis of d(CGGTACCG)
100 mg of "controlled pore glass" (CPG) loaded with a total of 8 umol of N-isobutyryldeoxyguanine (compare Tetrahedron Lett. 24, 747 (1983)) are consecutively condensed with the 5'-dimethoxytritylated N-acylated β-cyanoethyl N,N-diisopropylphosphoramidites of the deoxynucleosides C, C, A, T, G, G and C, in each case 20 to 25 equivalents of the phosphoramidite in acetonitrile being activated with 75-80 equivalents of sublimed tetrazole. The condensations are complete within 30 minutes at the most; the coupling yield is greater than 94%. After each condensation, oxidation with I2 /H2 O and blocking of unreacted 5'--OH groups with acetic anhydride are carried out. Then the dimethoxytrityl group is eliminated either with 3% trichloroacetic acid in nitromethane/1% methanol or ZnBr2 /nitromethane/1% H2 O.
The overall yield of the protected octanucleotide at the end of all condensation steps is 55% based on carrier-bound deoxyguanosine.
Complete deprotection and cleavage off from the carrier is achieved in one step by reaction of the glass beads with concentrated aqueous ammonia (3 ml) at 50° C. for 16 hours. The glass beads are then thoroughly washed with 50% aqueous methanol (3 times with 3 ml each time). The liquid phase is removed by evaporation (removal of the methanol) and freeze-drying. Then an aliquot is filtered through a millipore filter and purified by HPLC or RP 18 as can be seen in FIG. 3.
The fractions which contain the 5'-dimethoxytritylated oligonucleotide are collected; the volatile buffer is removed in a rotary evaporator in vacuo, 1 ml of 80% strength acetic acid is added to the residue. After 45 minutes at room temperature, the acetic acid is removed by freeze-drying.
The material thus obtained is phosphorylated in the customary manner (Liebigs Ann. Chem. 1978, 982) with T4-polynucleotide kinase and γ-32 P-ATP. The resulting product is characterized by polyacrylamide gel electrophoresis comparing with a homo-oligo-dT chain length standard (Nucleic Acids Res. 6, 2096 (1979), FIG. 4) and by sequencing according to FIG. 5 (Liebigs Ann. Chem. 1978, 982).
FIGS. 6a to 6c show the results (HPLC, gel electrophoresis, sequencing) of the synthesis of d(GGGATCCC) using the nucleoside β-cyanoethyl N,N-dimethylphosphoramidites, FIGS. 6a to 6c show the results (HPLC, g, electrophoresis, sequencing) of the synthesis of d(GGGATATCCC) using the nucleoside β-cyanoethyl N,N-morpholinophosphoramidites.
The results given in FIGS. 3, 6a and 7a were obtained by using a gradient from 10 to 25 vol. % CH3 CN, 5 min, and 25 to 29 vol. % CH3 CN, 30 min, in 0.1M triethylammonium acetate at pH 7.0. ##STR10##
                                  TABLE 1                                 
__________________________________________________________________________
Physical data of β-cyanoethyl phosphoramidochloridites               
         3a             3b             3c                                 
Compound L = N,N-dimethylamino                                            
                        L = N,N-diisopropylamino                          
                                       L = N-morpholino                   
__________________________________________________________________________
Boiling point                                                             
         90-92°/0.6 nm                                             
                        103-5°/0.06 nm                             
                                       --                                 
Chemical shift.sup.(2)                                                    
         175.97 ppm     179.82 ppm     168.22 ppm                         
in .sup.31 P NMR in                                                       
CH.sub.3 CN                                                               
Chemical shift in                                                         
         4.01, 4.17(2t, POCH.sub.2, 2H)                                   
                        4.02, 4.2(2t, POCH.sub.2, 2H)                     
                                       3.96, 4.1(2t, POCH.sub.2, 2H)      
.sup.1 H NMR in ppm                                                       
         2.71(t, CH.sub.2CN, 2H)                                          
                        3.8(m, N(CH).sub.2, 2H)                           
                                       3.67(t, O(CH.sub.2).sub.2, 4H)     
         2.7(d, N(CH.sub.3).sub.2, 6H)                                    
                        2.77(t, CH.sub.2 CH, 2H)                          
                                       3.17(m, PN(CH.sub.2).sub.2, 4H)    
                        1.29(d, NCH(CH.sub.3).sub.2, 12H)                 
                                       2.74(t, CH.sub.2CN.sub.2, 2H)      
 Mass spectrum                                                            
                         ##STR11##                                        
                                        ##STR12##                         
         (Cl), 136(C.sub.2 H.sub.6 N), 110                                
                        (Cl), 166(C.sub.3 H.sub.4 NO),                    
                                       (Cl), 152(C.sub.3 H.sub.4 NO),     
         (C.sub.3 H.sub.4 NO)                                             
                        136(C.sub.6 H.sub.14 N)                           
                                       136(C.sub.4 H.sub.8 O)             
__________________________________________________________________________
 .sup.(1) The crude product after removal of amine hydrochloride and      
 compounds volatile under high vacuum at room temperature has a purity of 
 93-95% according to the .sup.31 P NMR spectrum                           
 .sup.(2) The chemical shifts are determined in acetoned.sub.6 with 80%   
 strength H.sub.3 PO.sub.4 as the external standard.                      

Claims (19)

We claim:
1. A process for the preparation of oligonucleotides of the .[.general.]. formula I ##STR13## in which B denotes a nucleoside base, R1 denotes hydrogen, hydroxyl or hydroxyl which is protected by .Iadd., where appropriate, .Iaddend.a removable protective group and n denotes an integer from 1 to 200, comprising the steps of
(a) reacting a nucleoside of the .[.general.]. formula II ##STR14## in which R1 as defined as above, and R2 denotes a removable protective group and B' denotes the nucleotide base B protected by the protective groups which can be eliminated, with a phosphine derivative of the .[.general.]. formula III ##STR15## in which R3 is a protective group which can be eliminated, and X and L are groups which react with hydroxyl groups in the sugar moieties of the nucleotides or nucleosides, in the presence of a base to thereby form a nucleotide phosphite
(b) reacting the nucleotide phosphite obtained in step (a) and represented by the formula IV: ##STR16## in which B', R1, R2, R3 and L are as defined above, with a nucleoside, of the .[.general.]. formula V, bound to a polymeric carrier ##STR17## in which B' and R1 are as defined above and C denotes the polymeric carrier;
(c) oxidizing the carrier-bound nucleoside-nucleotides obtained in step (b) and represented by the formula: ##STR18## in which B', R1, R2, R3 and C are as defined above, with formation of phosphotriester groups,
(d) blocking free primary 5'--OH groups, which have not been reacted in the reaction according to step (b), with permanent protective groups;
(e) eliminating the protective group R2 ;
(f) optionally repeating steps (a) to (e) to introduce further nucleoside phosphate or oligonucleoside phosphate units; and
(g) cleaving the nucleoside carrier bond and optionally eliminating the protective groups present in the oligonucleoside phosphates,
which process comprises using in step (a) as the phosphine derivative of the .[.general.]. formula III a compound in which R3 denotes a group of the formula VII ##STR19## in which the groups Y, which can be identical or different, represent hydrogen, methyl, and/or ethyl and Z represents an electron-attracting group, where, in the phosphine derivative of the formula III, X is chlorine, bromine, CN or SCN and L is CN or SCN, a secondary amino radical of the formula (VIII)
--NR.sub.2.sup.4                                           ( VIII)
where the groups R4 are primary, secondary, or tertiary alkyl radicals having .Badd.1-10 carbon atoms, or together form a cycloalkyl radical having 5-7 carbon atoms, which can contain one or two nitrogen, oxygen, or sulfur atoms as hereoatoms, or are imidazole, triazole, tetrazole, 3-nitro-1,2,4-triazole, thiazole, pyrrole, benzotriazole, benzohydroxytriazole, imidazole substituted in the phenyl moiety, triazole substituted in the phenyl moiety, tetrazole substituted in the phenyl moiety, 3-nitro-1,2,4-triazole substituted in the phenyl moiety, thiazole substituted in the phenyl moiety, pyrrole substituted in the phenyl moiety, benzotriazole substituted in the phenyl moiety, or benzohydroxytriazole substituted in the phenyl moiety.
2. The process as claimed in claim 1, in which is used a phosphine derivative of the formula III in which X is chlorine or bromine, and L is a secondary amino radical of the formula (VIII)
--NR.sub.2.sup.4                                           (VIII)
where the groups R4 are primary, secondary or tertiary alkyl radicals having 1-10 carbon atoms, or together form a cycloalkyl radical having 5-7 carbon atoms, which can contain one or two nitrogen, oxygen or sulfur atoms as heteroatoms, or are imidazole, triazole, tetrazole, 3-nitro-1,2,4-triazole, thiazole, pyrrole, benzotriazole, benzohydroxytriazole, imidazole substituted in the phenyl moiety, triazole substituted in the phenyl moiety, tetrazole substituted in the phenyl moiety, 3-nitro-1,2,4-triazole substituted in the phenyl moiety, thiazole substituted in the phenyl moiety, pyrrole substituted in the phenyl moiety, benzotriazole substituted in the phenyl moiety, or benzohydroxytrizole substituted in the phenyl moiety.
3. The process as claimed in claim 1 or 2, in which is used a phosphine derivative of the formula (III) in which X is chlorine, L is an N,N-dimethylamino, diethylamino or -diisopropylamino group or N-morpholino group, and R3 is a β-cyanoethyl group.
4. A method of preparing oligonucleotides of the .[.general.]. formula: ##STR20## wherein B is a nucleoside base, R1 is hydrogen, hydroxyl or hydroxyl which is protected by removable nucleoside protective groups, and n denotes an integer from 1 to 200, comprising the steps of:
(a) reacting a nucleotide phosphite represented by the formula: ##STR21## wherein B' is a nucleoside base B protected by .Iadd., where appropriate, .Iaddend.a base protective group which can be eliminated, R1 is as defined above, R2 is 4,4' dimethoxytrityl or 4,4',4" trimethoxytrityl; and L is N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, or N-morpholino, with a nucleoside bound to a polymeric carrier, of the .[.general.]. formula: ##STR22## wherein B' and R1 are as defined above and C represents the polymeric carrier, to produce a carrier bound nucleoside-nucleotide of the formula: ##STR23## wherein B', R1, R2, R3 and C are as defined above; (b) oxidizing the carrier bound nucleoside-nucleotide;
(c) blocking free primary 5'--OH groups, which have not been reacted in the reaction of step (a), with permanent protective groups;
(d) eliminating the protecting group R2 ;
(f) repeating steps (a) to (d) to introduce further nucleoside phosphate units; and
(g) cleaving the nucleoside-carrier bond and optionally eliminating protective groups present in the oligonucleoside phosphates.
5. A method of synthesizing oligonucleotides, comprising the steps of:
(a) coupling a nucleoside β-cyanoethyl-protected phosphoramidite to a carrier-bound nucleoside to produce a carrier bound nucleoside-nucleotide having a phosphite triester linkage;
(b) oxidizing the phosphite triester to form a phosphate triester;
(c) optionally coupling additional nucleoside β-cyanoethyl-protected phosphoramidites to the carrier bound nucleoside-nucleotide and, after each coupling step, oxidizing the resulting phosphite triester to form a phosphate triester, to form a carrier bound polynucleotide;
(d) removing the β-cyanoethyl protecting groups; and
(e) removing the polynucleotide from the carrier.
6. A method of claim 5, wherein the nucleoside β-cyanoethyl phosphoramidite is a nucleoside β-cyanoethyl N,N-dimethylphosphoramidite, N,N-diethylphosphoramidite, .[.N,N-dipropylphosphoramidite.]. .Iadd.N,N-diisopropylphosphoramidite .Iaddend.or N,N-morpholino phosphoramidite.
7. A method of claim 6, wherein the carrier is controlled port glass.
8. A method of claim 7, wherein the β-cyanoethyl protecting group is removed with simultaneous removal of the polynucleotide from the carrier, by concentrated aqueous ammonia.
9. In a method of polynucleotide synthesis, comprising sequentially coupling nucleotide phosphoramidites to produce a polynucleotide, wherein the phosphorus atoms of the nucleotide phosphoramidites are protected by methyl groups, the improvement wherein the phosphorus protecting group are cyanoethyl groups.
10. A method of synthesizing oligonucleotides, comprising the steps of:
a. coupling a nucleoside β-cyanoethyl-protected phosphoramidite to a nucleoside, the nucleoside being bound to a polymeric carrier via an ester bond to produce a carrier-bound nucleoside-nucleotide having a phosphite triester linkage;
b. oxidizing the phosphite triester to form a phosphate triester linkage;
c. sequentially coupling additional nucleoside β-cyanoethyl protected phosphoramidite to the carrier-bound nucleoside-nucleotide, and after each coupling step, oxidizing the resulting phosphite triester linkage to a phosphate triester to produce a carrier-bound polynucleotide;
d. treating the carrier bound polynucleotide with concentrated ammonia to remove the β-cyanoethyl phosphate protecting group and hydrolyzing the ester bond to the carrier to remove the polynucleotide from the carrier.
11. A method of claim 10, wherein the nucleoside β-cyanoethyl phosphoramidite is a nucleoside β-cyanoethyl N,N-dimethylphosphoramidite, N,N-diethylphosphoramidite; .[.N,N-dispropylphosphoramidite.]. .Iadd.N,N-diispropylphosphoramidite .Iaddend.or N,N-morpholino phosphoramidite.
12. A method of claim 10, wherein the carrier is controlled pore glass.
13. A protected nucleotide having the formula: ##STR24## where, B' is a nucleoside base protected .Iadd., where appropriate, .Iaddend.by a base protective group which can be eliminated;
R1 is H, OH, or a hydroxyl group which is protected by a removable nucleoside protective group;
R2 is a removable protective group;
R3 is ##STR25## L is CN, SCN, or NR2 4 ; R4 is a primary, secondary or tertiary alkyl radical having 1-10 carbon atoms, or R2 4 is a cycloalkyl radical having 5-7 carbon atoms or a cycloalkyl radical having 5-7 atoms comprising atoms and one or two nitrogen, oxygen or sulfur atoms as heteroatoms;
Y is H, CH3, or CH2 CH3 ; and Z is a .[.halgen.]. .Iadd.halogen .Iaddend.CN, NO2, phenyl substituted in the o, o' or p positions with a halogen, CN or NO2 radical, phenylthio, phenylsulfoxy, or phenylsulfonyl, where the phenyl radicals, may be substituted in the o, o' or p positions with a halgen, CN or NO2 radical, or where the group ##STR26## may be replaced by CF3, CCl3, or CBr3.
14. A protected nucleotide as in claim 13, wherein Z is CN.
15. A protected nucleotide as in claim 14, wherein R3 l is CH2 --CH2 --CN.
16. A protected nucleotide as in claim 13, wherein R2 is 4,4'-dimethoxytrityl or 4,4"-trimethoxytrityl.
17. A protected nucleotide having the formula: ##STR27## where,
R1 is H, OH, or a hydroxyl group which is protected .Iadd., where appropriate, .Iaddend.by a removable nucleoside protective group;
R2 is 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytrityl;
B' is a nucleoside base protected by a base protective group which can be eliminated
R3 is CH2 --CH2 --CN; and
L is N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino or N-morpholino.
18. A protected nucleotide having the formula: ##STR28## where, R1 is H, OH, or a hydroxyl group which is protected by a protective group selected from the group consisting of trityl groups, acyl groups and silyl ether groups;
R2 is 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytrityl;
B' is a nucleoside base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and analogs thereof which are protected by acyl groups or Schiff bases;
R3 is CH2 --CH2 --CN; and
L is N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, or N-morpholino.
19. A protected nucleotide of claim 18, wherein .[.R1 .]. .Iadd.R1 .Iaddend. is H and B' is adenine, guanine, cytosine, thymine or uracil wherein the adenine or .[.guanine.]. .Iadd.cytosine .Iaddend.is protected by a benzoyl group and the guanine is protected by an .[.isobutyl.]. .Iadd.isobutyryl .Iaddend.group.
US07/481,572 1983-08-18 1990-02-16 Process for the preparation of oligonucleotides Expired - Lifetime USRE34069E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/481,572 USRE34069E (en) 1983-08-18 1990-02-16 Process for the preparation of oligonucleotides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19833329892 DE3329892A1 (en) 1983-08-18 1983-08-18 METHOD FOR PRODUCING OLIGONUCLEOTIDES
US06/752,178 US4725677A (en) 1983-08-18 1984-08-10 Process for the preparation of oligonucleotides
US07/481,572 USRE34069E (en) 1983-08-18 1990-02-16 Process for the preparation of oligonucleotides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06752178 Reissue 1984-08-10

Publications (1)

Publication Number Publication Date
USRE34069E true USRE34069E (en) 1992-09-15

Family

ID=27191213

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/481,572 Expired - Lifetime USRE34069E (en) 1983-08-18 1990-02-16 Process for the preparation of oligonucleotides

Country Status (1)

Country Link
US (1) USRE34069E (en)

Cited By (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428149A (en) * 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5510476A (en) * 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
US5734041A (en) * 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US5760209A (en) * 1997-03-03 1998-06-02 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
US5902881A (en) * 1997-03-03 1999-05-11 Isis Pharmaceuticals, Inc. Reagent useful for synthesizing sulfurized oligonucleotide analogs
US5925732A (en) 1994-09-21 1999-07-20 Isis Pharmaceuticals, Inc. Chemical reaction apparatus for performing multiple reaction on a surface and collecting the product
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US5959100A (en) 1996-03-27 1999-09-28 Nexstar Pharmaceuticals, Inc. Pyrimidine nucleosides as therapeutic and diagnostic agents
US6069243A (en) 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US6160152A (en) 1998-02-10 2000-12-12 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6172217B1 (en) 1996-12-27 2001-01-09 Isis Pharmaceuticals Inc. Method of synthesizing phosphorothioate oligonucleotides
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6239220B1 (en) 1998-07-17 2001-05-29 Isis Pharmaceuticals, Inc. Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis
US6274725B1 (en) 1998-06-02 2001-08-14 Isis Pharmaceuticals, Inc. Activators for oligonucleotide synthesis
US6291170B1 (en) 1989-09-22 2001-09-18 Board Of Trustees Of Leland Stanford University Multi-genes expression profile
US6294664B1 (en) 1993-07-29 2001-09-25 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US6326479B1 (en) 1998-01-27 2001-12-04 Boston Probes, Inc. Synthetic polymers and methods, kits or compositions for modulating the solubility of same
US6326478B1 (en) 1998-07-08 2001-12-04 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6335437B1 (en) 1998-09-07 2002-01-01 Isis Pharmaceuticals, Inc. Methods for the preparation of conjugated oligomers
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US6335439B1 (en) 1998-06-11 2002-01-01 Isis Pharmaceuticals, Inc. Method of preparing phosphoramidites
US6399765B1 (en) 1999-03-17 2002-06-04 Isis Pharmaceuticals, Inc. Methods for removing dimethoxytrityl groups from oligonucleotides
US6414135B1 (en) 1999-07-07 2002-07-02 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate monomers and related compounds
US6440943B1 (en) 1998-07-14 2002-08-27 Isis Pharmaceuticals, Inc. Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6476216B1 (en) 1995-10-20 2002-11-05 Mcgill University Preparation of phosphorothioate oligomers
US20020164629A1 (en) * 2001-03-12 2002-11-07 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US6528631B1 (en) 1993-09-03 2003-03-04 Isis Pharmaceuticals, Inc. Oligonucleotide-folate conjugates
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US6534639B1 (en) 1999-07-07 2003-03-18 Isis Pharmaceuticals, Inc. Guanidinium functionalized oligonucleotides and method/synthesis
US6600032B1 (en) 1998-08-07 2003-07-29 Isis Pharmaceuticals, Inc. 2′-O-aminoethyloxyethyl-modified oligonucleotides
US6610842B1 (en) 1999-05-06 2003-08-26 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomers using phosphoramidite compositions
US6639061B1 (en) 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US20030225284A1 (en) * 2002-04-11 2003-12-04 Quanlai Song Process for manufacturing purified phosphorodiamidite
US20030225262A1 (en) * 2002-04-11 2003-12-04 Sanghvi Yogesh S. Reagent and process for protecting active groups
US20030229221A1 (en) * 2000-05-12 2003-12-11 Avecia Limited Process for the preparation of phosphorothioate oligonucleotides
US6673912B1 (en) 1998-08-07 2004-01-06 Isis Pharmaceuticals, Inc. 2′-O-aminoethyloxyethyl-modified oligonucleotides
US20040009938A1 (en) * 1998-08-07 2004-01-15 Muthiah Manoharan Methods of enhancing renal uptake of oligonucleotides
US20040082774A1 (en) * 1999-03-16 2004-04-29 Guzaev Andrei P. Novel phosphate and thiophosphate protecting groups
US6762298B2 (en) 1999-03-24 2004-07-13 The United States Of America As Represented By The Department Of Health And Human Services Thermolabile phosphorus protecting groups, associated intermediates and methods of use
US20040185491A1 (en) * 1998-02-26 2004-09-23 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6818395B1 (en) 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US6822088B2 (en) 2001-07-17 2004-11-23 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides on solid support
US6825338B2 (en) 2001-03-30 2004-11-30 Isis Pharmaceuticals, Inc. Labeled oligonucleotides, methods for making same, and compounds useful therefor
US20050020827A1 (en) * 2001-12-03 2005-01-27 Beaucage Serge L. Thermolabile hydroxyl protecting groups and methods of use
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US20050065290A1 (en) * 2003-09-19 2005-03-24 Shah Vipul J. Novel functionalized polymer for oligonucleotide purification
US6919437B1 (en) 1998-06-11 2005-07-19 Isis Pharmaceuticals, Inc. Synthetic methods and intermediates for triester oligonucleotides
US6967247B2 (en) 2002-07-24 2005-11-22 Isis Pharmaceuticals, Inc. Deprotection of phosphorus in oligonucleotide synthesis
US7002006B2 (en) 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
US20060040308A1 (en) * 2004-08-23 2006-02-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US20060051800A1 (en) * 2004-09-02 2006-03-09 Isis Pharmaceuticals, Inc. Polymeric beads for oligomer synthesis
US7030230B2 (en) 2002-10-25 2006-04-18 Isis Pharmaceuticals, Inc. Process of purifying phosphoramidites
US7049102B1 (en) 1989-09-22 2006-05-23 Board Of Trustees Of Leland Stanford University Multi-gene expression profile
US20060147942A1 (en) * 2004-12-30 2006-07-06 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7074563B2 (en) 1995-03-17 2006-07-11 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US7169916B2 (en) 2002-04-01 2007-01-30 Isis Pharmaceuticals, Inc. Chloral-free DCA in oligonucleotide synthesis
US7276599B2 (en) 2003-06-02 2007-10-02 Isis Pharmaceuticals, Inc. Oligonucleotide synthesis with alternative solvents
US20070249049A1 (en) * 2006-01-27 2007-10-25 Swayze Eric E 6-modified bicyclic nucleic acid analogs
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US20080009007A1 (en) * 2006-06-16 2008-01-10 Pacific Biosciences Of California, Inc. Controlled initiation of primer extension
US20080064867A1 (en) * 2006-09-11 2008-03-13 Sigma Aldrich Company Process for the synthesis of oligonucleotides
US7397546B2 (en) 2006-03-08 2008-07-08 Helicos Biosciences Corporation Systems and methods for reducing detected intensity non-uniformity in a laser beam
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US7476734B2 (en) 2005-12-06 2009-01-13 Helicos Biosciences Corporation Nucleotide analogs
US7482120B2 (en) 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US20090092981A1 (en) * 2007-08-15 2009-04-09 Swayze Eric E Tetrahydropyran nucleic acid analogs
EP2053406A2 (en) 2001-07-16 2009-04-29 caprotec bioanalytics GmbH Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US20090156792A1 (en) * 2006-05-11 2009-06-18 Seth Punit P Bis-modified bicyclic nucleic acid analogs
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
US20090213877A1 (en) * 2005-08-31 2009-08-27 Andreas Tunnermann Fiber laser
US20090263405A1 (en) * 2004-12-13 2009-10-22 Government Of The United States Of America Represented By The Secretary CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS
US20090305248A1 (en) * 2005-12-15 2009-12-10 Lander Eric G Methods for increasing accuracy of nucleic acid sequencing
US7635562B2 (en) 2004-05-25 2009-12-22 Helicos Biosciences Corporation Methods and devices for nucleic acid sequence determination
US7645596B2 (en) 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US20100041866A1 (en) * 2006-03-24 2010-02-18 Archemix Corp. Solid Support Reagents for Synthesis
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US7695902B2 (en) 1996-06-06 2010-04-13 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2010101951A1 (en) 2009-03-02 2010-09-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20100331538A1 (en) * 2007-11-21 2010-12-30 Seth Punit P Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2011005861A1 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US20110053881A1 (en) * 2007-07-05 2011-03-03 Seth Punit P 6-Disubstituted Or Unsaturated Bicyclic Nucleic Acid Analogs
US20110077390A1 (en) * 2008-02-07 2011-03-31 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US20110092570A1 (en) * 2008-03-21 2011-04-21 Swayze Eric E Oligomeric compounds comprising tricyclic nucelosides and methods for their use
US20110130441A1 (en) * 2008-04-04 2011-06-02 Isis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleosides
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
US20110172294A1 (en) * 2008-09-24 2011-07-14 Seth Punit P Cyclohexenyl nucleic acids analogs
US7981604B2 (en) 2004-02-19 2011-07-19 California Institute Of Technology Methods and kits for analyzing polynucleotide sequences
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
US20110200528A1 (en) * 2008-06-23 2011-08-18 The Government Of The United States Of America Cyclized ngr peptide compounds, compositions, and methods of their use
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139695A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011156278A1 (en) 2010-06-07 2011-12-15 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011163121A1 (en) 2010-06-21 2011-12-29 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US8188059B2 (en) 2006-05-05 2012-05-29 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCGR
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
WO2013090457A2 (en) 2011-12-12 2013-06-20 Oncoimmunin Inc. In vivo delivery of oligonucleotides
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
WO2013154798A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2014031575A1 (en) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups
EP2708541A1 (en) 2003-11-13 2014-03-19 Isis Pharmaceuticals, Inc. 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
US8703728B2 (en) 2003-09-09 2014-04-22 Isis Pharmaceuticals, Inc. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US8883752B2 (en) 2008-10-24 2014-11-11 Isis Pharmaceuticals, Inc. 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US9096898B2 (en) 1998-05-01 2015-08-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015168172A1 (en) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
US9403865B2 (en) 2012-08-15 2016-08-02 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
WO2016137923A1 (en) 2015-02-23 2016-09-01 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
EP3067359A1 (en) 2008-09-23 2016-09-14 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US9701708B2 (en) 2013-01-31 2017-07-11 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
US9758546B2 (en) 2013-10-21 2017-09-12 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
US10036019B2 (en) 2014-03-17 2018-07-31 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
US10098959B2 (en) 2014-05-01 2018-10-16 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
US10266825B2 (en) 2002-11-05 2019-04-23 Ionis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US11613554B2 (en) 2018-04-13 2023-03-28 Bristol-Myers Squibb Company Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
EP4219516A2 (en) 2012-07-13 2023-08-02 Wave Life Sciences Ltd. Chiral control
WO2024035952A1 (en) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040099A1 (en) * 1980-05-14 1981-11-18 ens BIO LOGICALS INC. Polynucleotide synthesis
US4310662A (en) * 1979-12-26 1982-01-12 Genentech, Inc. Nucleosidic phosphorylating agent and methods
EP0061746A1 (en) * 1981-03-27 1982-10-06 University Patents, Inc. Phosphoramidite compounds and their use in producing oligonucleotides
EP0064796A2 (en) * 1981-05-12 1982-11-17 Unilever N.V. Phosphorylating agent and process for the phosphorylation of organic hydroxyl compounds
EP0090789A1 (en) * 1982-03-26 1983-10-05 Monsanto Company Chemical DNA synthesis
US4419509A (en) * 1981-08-24 1983-12-06 Eli Lilly And Company Process for de-cyanoethylating blocked nucleotides
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4476301A (en) * 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
EP0131993A2 (en) * 1983-07-01 1985-01-23 Stichting Katholieke Universiteit Phosphorylating agent; a process for the preparation thereof; a process for phosphorylating an organic hydroxyl or amine compound
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4591614A (en) * 1983-10-07 1986-05-27 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
US4605735A (en) * 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310662A (en) * 1979-12-26 1982-01-12 Genentech, Inc. Nucleosidic phosphorylating agent and methods
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
EP0040099A1 (en) * 1980-05-14 1981-11-18 ens BIO LOGICALS INC. Polynucleotide synthesis
EP0061746A1 (en) * 1981-03-27 1982-10-06 University Patents, Inc. Phosphoramidite compounds and their use in producing oligonucleotides
US4415732A (en) * 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
EP0064796A2 (en) * 1981-05-12 1982-11-17 Unilever N.V. Phosphorylating agent and process for the phosphorylation of organic hydroxyl compounds
US4419509A (en) * 1981-08-24 1983-12-06 Eli Lilly And Company Process for de-cyanoethylating blocked nucleotides
EP0090789A1 (en) * 1982-03-26 1983-10-05 Monsanto Company Chemical DNA synthesis
US4476301A (en) * 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4605735A (en) * 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
EP0131993A2 (en) * 1983-07-01 1985-01-23 Stichting Katholieke Universiteit Phosphorylating agent; a process for the preparation thereof; a process for phosphorylating an organic hydroxyl or amine compound
US4591614A (en) * 1983-10-07 1986-05-27 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
Beaucage and Caruthers (1981) Tet. Lett. 22:1859 1862. *
Beaucage and Caruthers (1981) Tet. Lett. 22:1859-1862.
Caruthers, M. H., Science 230:281 (1985). *
Clesen et al., "Tetrahedron Letters", vol. 25, No. 12, pp. 1307-1310, 1984.
Clesen et al., Tetrahedron Letters , vol. 25, No. 12, pp. 1307 1310, 1984. *
Gao, X. et al. Nucleic Acids Research 13(2):573 (1985). *
H. Koster et al., Nucleic Acids Research Symposium Series No. 7 (1980) pp. 39 61. *
H. Koster et al., Nucleic Acids Research Symposium Series No. 7 (1980) pp. 39-61.
Lelsinger et al., "Jour. of the Amer. Chem. Soc." vol. 98, No. 12, Jun. 1976, pp. 3655-3661.
Lelsinger et al., Jour. of the Amer. Chem. Soc. vol. 98, No. 12, Jun. 1976, pp. 3655 3661. *
Marugg et al., "Recl. Trav. Chim. Pays-Bas" vol. 103, pp. 97-98, 1984.
Marugg et al., Recl. Trav. Chim. Pays Bas vol. 103, pp. 97 98, 1984. *
Narang, "Tetrahedron", vol. 39, No. 1, pp. 3-22, 1983.
Narang, Tetrahedron , vol. 39, No. 1, pp. 3 22, 1983. *
Ogilvie, K. K. et al., Can J. Chem 58:2686 (1980). *
Urdea, M. S. et al. Nucleic Acids Research Symposium Ser. 16 (1985) pp. 257 260. *
Urdea, M. S. et al. Nucleic Acids Research Symposium Ser. 16 (1985) pp. 257-260.
V. Amarnath and A. D. Broom, Chemical Reviews 77(2)183 (1977). *
Zon, G. et al., Nucleic Acids Research 13(22):8181 (1985). *

Cited By (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291170B1 (en) 1989-09-22 2001-09-18 Board Of Trustees Of Leland Stanford University Multi-genes expression profile
US7049102B1 (en) 1989-09-22 2006-05-23 Board Of Trustees Of Leland Stanford University Multi-gene expression profile
US6861514B2 (en) 1991-10-24 2005-03-01 Isis Pharmaceuticals, Inc. Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US5955591A (en) 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
US5591843A (en) 1993-06-14 1997-01-07 Eaton; Bruce 5-modified pyrimidines from palladium catalyzed carbon-carbon coupling
US5633361A (en) * 1993-06-14 1997-05-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coupling and products
US5428149A (en) * 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US6294664B1 (en) 1993-07-29 2001-09-25 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US6528631B1 (en) 1993-09-03 2003-03-04 Isis Pharmaceuticals, Inc. Oligonucleotide-folate conjugates
US6974865B2 (en) 1994-04-07 2005-12-13 Isis Pharmaceuticals, Inc. C3′ -methylene hydrogen phosphonate oligomers and related compounds
US5510476A (en) * 1994-07-07 1996-04-23 Isis Pharmaceuticals, Inc. Carbocation scavenging during oligonucleotide synthesis
US5714597A (en) * 1994-07-07 1998-02-03 Isis Pharmaceuticals, Inc. Use of carbocation scavenger during oligonucleotide synthesis
US6558633B1 (en) 1994-09-21 2003-05-06 Isis Pharmaceuticals, Inc. Chemical reaction apparatus and methods
US6277334B1 (en) 1994-09-21 2001-08-21 Isis Pharmaceuticals, Inc. Chemical synthesis apparatus employing a droplet generator
US5925732A (en) 1994-09-21 1999-07-20 Isis Pharmaceuticals, Inc. Chemical reaction apparatus for performing multiple reaction on a surface and collecting the product
US20010028866A1 (en) * 1994-09-21 2001-10-11 Isis Pharmaceuticals, Inc. Chemical synthesis apparatus employing a droplet generator
US6124445A (en) 1994-11-23 2000-09-26 Isis Pharmaceuticals, Inc. Phosphotriester oligonucleotides, amidities and method of preparation
US7419787B2 (en) 1995-03-17 2008-09-02 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US7759065B2 (en) 1995-03-17 2010-07-20 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US7074563B2 (en) 1995-03-17 2006-07-11 Sequenom, Inc. Mass spectrometric methods for detecting mutations in a target nucleic acid
US20030114660A1 (en) * 1995-10-20 2003-06-19 George Just Preparation of phosphorothioate oligomers
US6861518B2 (en) 1995-10-20 2005-03-01 Mcgill University Preparation of phosphorothioate oligomers
US5734041A (en) * 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US6476216B1 (en) 1995-10-20 2002-11-05 Mcgill University Preparation of phosphorothioate oligomers
US6596857B1 (en) 1995-10-20 2003-07-22 Mcgill University Preparation of phosphorothioate oligomers
US6914138B2 (en) 1996-03-27 2005-07-05 Gilead Sciences, Inc. Urea nucleosides as therapeutic and diagnostic agents
US6441161B1 (en) 1996-03-27 2002-08-27 Gilead Sciences, Inc. Urea nucleosides as therapeutic and diagnostic agents
US5959100A (en) 1996-03-27 1999-09-28 Nexstar Pharmaceuticals, Inc. Pyrimidine nucleosides as therapeutic and diagnostic agents
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US7695902B2 (en) 1996-06-06 2010-04-13 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA
US6172217B1 (en) 1996-12-27 2001-01-09 Isis Pharmaceuticals Inc. Method of synthesizing phosphorothioate oligonucleotides
US6780989B2 (en) 1996-12-27 2004-08-24 Isis Pharmaceuticals, Inc. Diribonucleoside Phosphoramidites
US6403781B2 (en) 1996-12-27 2002-06-11 Isis Pharmaceuticals, Inc. Method of synthesizing phosphorothioate oligonucleotides
US6399831B1 (en) 1997-03-03 2002-06-04 Isis Pharmaceuticals, Inc. Reagent useful for synthesizing sulfurized oligonucleotide analogs
US5760209A (en) * 1997-03-03 1998-06-02 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
US5783690A (en) * 1997-03-03 1998-07-21 Isis Pharmaceuticals, Inc. Protecting group for synthesizing oligonucleotide analogs
US5902881A (en) * 1997-03-03 1999-05-11 Isis Pharmaceuticals, Inc. Reagent useful for synthesizing sulfurized oligonucleotide analogs
US6326479B1 (en) 1998-01-27 2001-12-04 Boston Probes, Inc. Synthetic polymers and methods, kits or compositions for modulating the solubility of same
US6770442B2 (en) 1998-01-27 2004-08-03 Boston Probes, Inc. Methods for modulating the solubility of synthetic polymers
US6160152A (en) 1998-02-10 2000-12-12 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US7273933B1 (en) * 1998-02-26 2007-09-25 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US20040185491A1 (en) * 1998-02-26 2004-09-23 Isis Pharmaceuticals, Inc. Methods for synthesis of oligonucleotides
US6531590B1 (en) 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
US9725764B2 (en) 1998-05-01 2017-08-08 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9540689B2 (en) 1998-05-01 2017-01-10 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9957561B2 (en) 1998-05-01 2018-05-01 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US10208341B2 (en) 1998-05-01 2019-02-19 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9458500B2 (en) 1998-05-01 2016-10-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9212393B2 (en) 1998-05-01 2015-12-15 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US10214774B2 (en) 1998-05-01 2019-02-26 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9096898B2 (en) 1998-05-01 2015-08-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7645596B2 (en) 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6642373B2 (en) 1998-06-02 2003-11-04 Isis Pharmaceuticals, Inc. Activators for oligonucleotide synthesis
US6274725B1 (en) 1998-06-02 2001-08-14 Isis Pharmaceuticals, Inc. Activators for oligonucleotide synthesis
US6846922B1 (en) 1998-06-02 2005-01-25 Isis Pharmaceuticals, Inc. Activators for oligonucleotide synthesis
US6919437B1 (en) 1998-06-11 2005-07-19 Isis Pharmaceuticals, Inc. Synthetic methods and intermediates for triester oligonucleotides
US6335439B1 (en) 1998-06-11 2002-01-01 Isis Pharmaceuticals, Inc. Method of preparing phosphoramidites
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US6326478B1 (en) 1998-07-08 2001-12-04 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6677471B2 (en) 1998-07-08 2004-01-13 Isis Pharmaceuticals, Inc. Intermediates for the synthesis of oligonucleotide analogues
US6521775B2 (en) 1998-07-08 2003-02-18 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6399756B1 (en) 1998-07-08 2002-06-04 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6440943B1 (en) 1998-07-14 2002-08-27 Isis Pharmaceuticals, Inc. Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages
USRE39464E1 (en) * 1998-07-14 2007-01-09 Isis Pharmaceuticals Inc. Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6239220B1 (en) 1998-07-17 2001-05-29 Isis Pharmaceuticals, Inc. Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis
US20040009938A1 (en) * 1998-08-07 2004-01-15 Muthiah Manoharan Methods of enhancing renal uptake of oligonucleotides
US6600032B1 (en) 1998-08-07 2003-07-29 Isis Pharmaceuticals, Inc. 2′-O-aminoethyloxyethyl-modified oligonucleotides
US6673912B1 (en) 1998-08-07 2004-01-06 Isis Pharmaceuticals, Inc. 2′-O-aminoethyloxyethyl-modified oligonucleotides
US6335437B1 (en) 1998-09-07 2002-01-01 Isis Pharmaceuticals, Inc. Methods for the preparation of conjugated oligomers
US6069243A (en) 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US20050182251A1 (en) * 1999-02-04 2005-08-18 Ravikumar Vasulinga T. Process for the synthesis of oligomeric compounds
US7199236B2 (en) 1999-02-04 2007-04-03 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US20050137390A1 (en) * 1999-02-04 2005-06-23 Ravikumar Vasulinga T. Process for the synthesis of oligomeric compounds
US20050137391A1 (en) * 1999-02-04 2005-06-23 Ravikumar Vasulinga T. Process for the synthesis of oligomeric compounds
US7186822B2 (en) 1999-02-04 2007-03-06 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US7227016B2 (en) 1999-02-04 2007-06-05 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US20040219577A1 (en) * 1999-02-04 2004-11-04 Ravikumar Vasulinga T. Process for the synthesis of oligomeric compounds
US20070265435A1 (en) * 1999-02-04 2007-11-15 Ravikumar Vasulinga T Process for the synthesis of oligomeric compounds
US7041816B2 (en) 1999-02-04 2006-05-09 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
US6462184B2 (en) 1999-02-12 2002-10-08 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6207819B1 (en) 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US20040082774A1 (en) * 1999-03-16 2004-04-29 Guzaev Andrei P. Novel phosphate and thiophosphate protecting groups
US6610837B1 (en) 1999-03-16 2003-08-26 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6399765B1 (en) 1999-03-17 2002-06-04 Isis Pharmaceuticals, Inc. Methods for removing dimethoxytrityl groups from oligonucleotides
US6794502B2 (en) 1999-03-17 2004-09-21 Isis Pharmaceuticals, Inc. Methods for removing dimethoxytrityl groups from oligonucleotides
US6965041B1 (en) 1999-03-24 2005-11-15 The United States Of America As Represented By The Department Of Health And Human Services N-acylphosphoramidites and their use in oligonucleotide synthesis
US6762298B2 (en) 1999-03-24 2004-07-13 The United States Of America As Represented By The Department Of Health And Human Services Thermolabile phosphorus protecting groups, associated intermediates and methods of use
US6610842B1 (en) 1999-05-06 2003-08-26 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomers using phosphoramidite compositions
US6818395B1 (en) 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US7462449B2 (en) 1999-06-28 2008-12-09 California Institute Of Technology Methods and apparatuses for analyzing polynucleotide sequences
US6911345B2 (en) 1999-06-28 2005-06-28 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US6639061B1 (en) 1999-07-07 2003-10-28 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate oligomers and related compounds
US6534639B1 (en) 1999-07-07 2003-03-18 Isis Pharmaceuticals, Inc. Guanidinium functionalized oligonucleotides and method/synthesis
US6593466B1 (en) 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6414135B1 (en) 1999-07-07 2002-07-02 Isis Pharmaceuticals, Inc. C3′-methylene hydrogen phosphonate monomers and related compounds
US6147200A (en) 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US20030229221A1 (en) * 2000-05-12 2003-12-11 Avecia Limited Process for the preparation of phosphorothioate oligonucleotides
US7227017B2 (en) * 2000-12-05 2007-06-05 Avecia Limited Process for the preparation of phosphorothioate oligonucleotides
US7297518B2 (en) 2001-03-12 2007-11-20 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US20020164629A1 (en) * 2001-03-12 2002-11-07 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US6825338B2 (en) 2001-03-30 2004-11-30 Isis Pharmaceuticals, Inc. Labeled oligonucleotides, methods for making same, and compounds useful therefor
EP2053406A2 (en) 2001-07-16 2009-04-29 caprotec bioanalytics GmbH Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US6822088B2 (en) 2001-07-17 2004-11-23 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides on solid support
US20050020827A1 (en) * 2001-12-03 2005-01-27 Beaucage Serge L. Thermolabile hydroxyl protecting groups and methods of use
US7355037B2 (en) 2001-12-03 2008-04-08 The United States Of America As Represented By The Department Of Health And Human Services Thermolabile hydroxyl protecting groups and methods of use
US20070123703A1 (en) * 2002-04-01 2007-05-31 Isis Pharmaceuticals, Inc. Chloral-free dca in oligonucleotide synthesis
US7759480B2 (en) 2002-04-01 2010-07-20 Isis Pharmaceuticals, Inc. Chloral-free DCA in oligonucleotide synthesis
US7169916B2 (en) 2002-04-01 2007-01-30 Isis Pharmaceuticals, Inc. Chloral-free DCA in oligonucleotide synthesis
US20030225262A1 (en) * 2002-04-11 2003-12-04 Sanghvi Yogesh S. Reagent and process for protecting active groups
US7057062B2 (en) 2002-04-11 2006-06-06 Isis Pharmaceuticals, Inc. Process for manufacturing purified phosphorodiamidite
US20030225284A1 (en) * 2002-04-11 2003-12-04 Quanlai Song Process for manufacturing purified phosphorodiamidite
US6800751B2 (en) 2002-04-11 2004-10-05 Isis Pharmaceuticals, Inc. Reagent and process for protecting nucleoside hydroxyl groups
US6967247B2 (en) 2002-07-24 2005-11-22 Isis Pharmaceuticals, Inc. Deprotection of phosphorus in oligonucleotide synthesis
US7030230B2 (en) 2002-10-25 2006-04-18 Isis Pharmaceuticals, Inc. Process of purifying phosphoramidites
US10266825B2 (en) 2002-11-05 2019-04-23 Ionis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7002006B2 (en) 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
US7276599B2 (en) 2003-06-02 2007-10-02 Isis Pharmaceuticals, Inc. Oligonucleotide synthesis with alternative solvents
US8703728B2 (en) 2003-09-09 2014-04-22 Isis Pharmaceuticals, Inc. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050065290A1 (en) * 2003-09-19 2005-03-24 Shah Vipul J. Novel functionalized polymer for oligonucleotide purification
US7125945B2 (en) 2003-09-19 2006-10-24 Varian, Inc. Functionalized polymer for oligonucleotide purification
US9657344B2 (en) 2003-11-12 2017-05-23 Fluidigm Corporation Short cycle methods for sequencing polynucleotides
US9012144B2 (en) 2003-11-12 2015-04-21 Fluidigm Corporation Short cycle methods for sequencing polynucleotides
US7491498B2 (en) 2003-11-12 2009-02-17 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US20070122828A1 (en) * 2003-11-12 2007-05-31 Stanley Lapidus Short cycle methods for sequencing polynucleotides
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US7897345B2 (en) 2003-11-12 2011-03-01 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
EP2708541A1 (en) 2003-11-13 2014-03-19 Isis Pharmaceuticals, Inc. 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
US7981604B2 (en) 2004-02-19 2011-07-19 California Institute Of Technology Methods and kits for analyzing polynucleotide sequences
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US7635562B2 (en) 2004-05-25 2009-12-22 Helicos Biosciences Corporation Methods and devices for nucleic acid sequence determination
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US20060040308A1 (en) * 2004-08-23 2006-02-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US7427675B2 (en) 2004-08-23 2008-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US20080097028A1 (en) * 2004-09-02 2008-04-24 Lsis Pharmaceuticals, Inc. Polymeric beads for oligomer synthesis
US20060051800A1 (en) * 2004-09-02 2006-03-09 Isis Pharmaceuticals, Inc. Polymeric beads for oligomer synthesis
US7348391B2 (en) 2004-09-02 2008-03-25 Isis Pharmaceuticals, Inc. Polymeric beads for oligomer synthesis
US7700706B2 (en) 2004-09-02 2010-04-20 Isis Pharmaceuticals, Inc. Polymeric beads for oligomer synthesis
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20090263405A1 (en) * 2004-12-13 2009-10-22 Government Of The United States Of America Represented By The Secretary CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US20060147942A1 (en) * 2004-12-30 2006-07-06 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7482120B2 (en) 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US9868978B2 (en) 2005-08-26 2018-01-16 Fluidigm Corporation Single molecule sequencing of captured nucleic acids
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US20090213877A1 (en) * 2005-08-31 2009-08-27 Andreas Tunnermann Fiber laser
US7476734B2 (en) 2005-12-06 2009-01-13 Helicos Biosciences Corporation Nucleotide analogs
US20090305248A1 (en) * 2005-12-15 2009-12-10 Lander Eric G Methods for increasing accuracy of nucleic acid sequencing
US20070249049A1 (en) * 2006-01-27 2007-10-25 Swayze Eric E 6-modified bicyclic nucleic acid analogs
EP2314594A1 (en) 2006-01-27 2011-04-27 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7399845B2 (en) 2006-01-27 2008-07-15 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7741457B2 (en) 2006-01-27 2010-06-22 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US8022193B2 (en) 2006-01-27 2011-09-20 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US20100216979A1 (en) * 2006-01-27 2010-08-26 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
EP2332951A2 (en) 2006-01-27 2011-06-15 ISIS Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
US7397546B2 (en) 2006-03-08 2008-07-08 Helicos Biosciences Corporation Systems and methods for reducing detected intensity non-uniformity in a laser beam
US20100041866A1 (en) * 2006-03-24 2010-02-18 Archemix Corp. Solid Support Reagents for Synthesis
US8362234B2 (en) 2006-03-24 2013-01-29 Archemix Llc Solid support reagents for synthesis
US8372967B2 (en) 2006-05-05 2013-02-12 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCCR
US8188059B2 (en) 2006-05-05 2012-05-29 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of GCGR
US8673871B2 (en) 2006-05-05 2014-03-18 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression ApoB
US9045754B2 (en) 2006-05-05 2015-06-02 Isis Pharmaceuticals, Inc. Short antisense compounds with gapmer configuration
US8969316B2 (en) 2006-05-05 2015-03-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of DGAT2
US8362232B2 (en) 2006-05-05 2013-01-29 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of SGLT2
US7547684B2 (en) 2006-05-11 2009-06-16 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US20070287831A1 (en) * 2006-05-11 2007-12-13 Isis Pharmaceuticals, Inc 5'-modified bicyclic nucleic acid analogs
US8088746B2 (en) 2006-05-11 2012-01-03 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US20090192302A1 (en) * 2006-05-11 2009-07-30 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US20090156792A1 (en) * 2006-05-11 2009-06-18 Seth Punit P Bis-modified bicyclic nucleic acid analogs
US20100121045A1 (en) * 2006-05-11 2010-05-13 Seth Punit P Bis-modified bicyclic nucleic acid analogs
US20100184966A1 (en) * 2006-05-11 2010-07-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7750131B2 (en) 2006-05-11 2010-07-06 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US8030467B2 (en) 2006-05-11 2011-10-04 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US8268980B2 (en) 2006-05-11 2012-09-18 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
US20080009007A1 (en) * 2006-06-16 2008-01-10 Pacific Biosciences Of California, Inc. Controlled initiation of primer extension
US20080064867A1 (en) * 2006-09-11 2008-03-13 Sigma Aldrich Company Process for the synthesis of oligonucleotides
US8138330B2 (en) 2006-09-11 2012-03-20 Sigma-Aldrich Co. Llc Process for the synthesis of oligonucleotides
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US20110053881A1 (en) * 2007-07-05 2011-03-03 Seth Punit P 6-Disubstituted Or Unsaturated Bicyclic Nucleic Acid Analogs
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
US8088904B2 (en) 2007-08-15 2012-01-03 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US8796437B2 (en) 2007-08-15 2014-08-05 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US9005906B2 (en) 2007-08-15 2015-04-14 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US8440803B2 (en) 2007-08-15 2013-05-14 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US20090092981A1 (en) * 2007-08-15 2009-04-09 Swayze Eric E Tetrahydropyran nucleic acid analogs
US20100331538A1 (en) * 2007-11-21 2010-12-30 Seth Punit P Carbocyclic alpha-l-bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
US8530640B2 (en) 2008-02-07 2013-09-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US20110077390A1 (en) * 2008-02-07 2011-03-31 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US20110092570A1 (en) * 2008-03-21 2011-04-21 Swayze Eric E Oligomeric compounds comprising tricyclic nucelosides and methods for their use
US9428750B2 (en) 2008-03-21 2016-08-30 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
US8426378B2 (en) 2008-03-21 2013-04-23 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucelosides and methods for their use
US8993528B2 (en) 2008-03-21 2015-03-31 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucelosides and methods for their use
US9290534B2 (en) 2008-04-04 2016-03-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
US20110130441A1 (en) * 2008-04-04 2011-06-02 Isis Pharmaceuticals, Inc. Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleosides
US8636978B2 (en) 2008-06-23 2014-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclized NGR peptide compounds, compositions, and methods of their use
US20110200528A1 (en) * 2008-06-23 2011-08-18 The Government Of The United States Of America Cyclized ngr peptide compounds, compositions, and methods of their use
EP3067359A1 (en) 2008-09-23 2016-09-14 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
US8604192B2 (en) 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
US20110172294A1 (en) * 2008-09-24 2011-07-14 Seth Punit P Cyclohexenyl nucleic acids analogs
US9409934B2 (en) 2008-09-24 2016-08-09 Ionis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
US9738895B2 (en) 2008-10-24 2017-08-22 Ionis Pharmaceuticals, Inc. Oligomeric compounds and methods
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
US8883752B2 (en) 2008-10-24 2014-11-11 Isis Pharmaceuticals, Inc. 5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
US8536320B2 (en) 2009-02-06 2013-09-17 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
EP2669290A1 (en) 2009-03-02 2013-12-04 Alnylam Pharmaceuticals Inc. Nucleic Acid Chemical Modifications
WO2010101951A1 (en) 2009-03-02 2010-09-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
EP3424939A1 (en) 2009-03-02 2019-01-09 Alnylam Pharmaceuticals Inc. Nucleic acid chemical modifications
WO2011005861A1 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9321799B2 (en) 2010-04-28 2016-04-26 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
WO2011139699A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139695A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
US11084844B2 (en) 2010-04-28 2021-08-10 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
US11268094B2 (en) 2010-04-28 2022-03-08 Ionis Pharmaceuticals, Inc 5′ modified nucleosides and oligomeric compounds prepared therefrom
EP3091027A1 (en) 2010-04-28 2016-11-09 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
US8993738B2 (en) 2010-04-28 2015-03-31 Isis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
EP3173419A1 (en) 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011156278A1 (en) 2010-06-07 2011-12-15 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011163121A1 (en) 2010-06-21 2011-12-29 Alnylam Pharmaceuticals, Inc. Multifunctional copolymers for nucleic acid delivery
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
WO2013090457A2 (en) 2011-12-12 2013-06-20 Oncoimmunin Inc. In vivo delivery of oligonucleotides
WO2013154798A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP4219516A2 (en) 2012-07-13 2023-08-02 Wave Life Sciences Ltd. Chiral control
US9403865B2 (en) 2012-08-15 2016-08-02 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
WO2014031575A1 (en) 2012-08-20 2014-02-27 The Regents Of The University Of California Polynucleotides having bioreversible groups
US9701708B2 (en) 2013-01-31 2017-07-11 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
US9758546B2 (en) 2013-10-21 2017-09-12 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
US10036019B2 (en) 2014-03-17 2018-07-31 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
US10221416B2 (en) 2014-04-24 2019-03-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
EP3647318A1 (en) 2014-04-28 2020-05-06 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
WO2015168172A1 (en) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
US9926556B2 (en) 2014-04-28 2018-03-27 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
EP3811977A1 (en) 2014-05-01 2021-04-28 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
US10098959B2 (en) 2014-05-01 2018-10-16 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
EP4223315A2 (en) 2014-05-01 2023-08-09 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10450342B2 (en) 2015-02-23 2019-10-22 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
WO2016137923A1 (en) 2015-02-23 2016-09-01 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
US11613554B2 (en) 2018-04-13 2023-03-28 Bristol-Myers Squibb Company Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
WO2024035952A1 (en) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites

Similar Documents

Publication Publication Date Title
USRE34069E (en) Process for the preparation of oligonucleotides
US4725677A (en) Process for the preparation of oligonucleotides
US6028182A (en) Methylphosphonic acid esters, processes for their preparation, and their use
KR102531388B1 (en) Alkoxy phenyl derivatives, nucleoside protectors and nucleotide protectors, methods for preparing oligonucleotides, and methods for removing substituents
AU4413599A (en) Activators for oligonucleotide synthesis
JPH035495A (en) Modified phosphor amidite process for producing modified nucleic acid
US5071974A (en) Compositions and methods for the synthesis of oligonucleotides having 5'-phosphorylated termini
US5623068A (en) Synthesis of DNA using substituted phenylacetyl-protected nucleotides
WO2017111137A1 (en) Oligonucleotide manufacturing method
US6380378B1 (en) Nucleotide compound, nucleotide block oligonucleotide, and method for producing them
EA003091B1 (en) Solution phase synthesis of oligonucleotides
US5936077A (en) Solid phase synthesis of oligonucleotides
EP0611075B1 (en) Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
EP1317466B1 (en) Synthons for oligonucleotide synthesis
US20070004911A1 (en) Silylated oligonucleotide compounds
US5134228A (en) Nucleoside-3'-phosphites for synthesis of oligonucleotides
JPS6330317B2 (en)
JP7452549B2 (en) Phosphoramidite activator
JPH0588240B2 (en)
Dabkowski et al. Synthesis of phosphorofluoridates and phosphorofluoridothioates via the phosphoramidite approach
WO2019212063A1 (en) Optically active segment for stereocontrolled oligonucleotide synthesis, production method for same, and stereocontrolled oligonucleotide synthesis method using same
Cramer et al. Nucleotides, Part LX, Synthesis and Characterization of New 2′‐O‐Methylriboside 3′‐O‐Phosphoramidites Useful for the Solid‐Phase Synthesis of 2′‐O‐Methyloligoribonucleotides
JP3580158B2 (en) Monoalkylamino-type phosphoramidite compounds
JP2020203902A (en) Alkoxyphenyl derivatives, protected nucleosides and protected nucleotides, production methods of oligonucleotides and methods for removing substituents
JPH10259192A (en) Production of phosphorothioate diester

Legal Events

Date Code Title Description
AS Assignment

Owner name: MILLIPORE CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BIOSYNTECH GMBH;REEL/FRAME:006495/0624

Effective date: 19930329

RR Request for reexamination filed

Effective date: 19930701

AS Assignment

Owner name: MILLIPORE INVESTMENT HOLDINGS LTD., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLIPORE CORPORATION;REEL/FRAME:006862/0716

Effective date: 19931214

RR Request for reexamination filed

Effective date: 19940112

AS Assignment

Owner name: PERSEPTIVE BIOSYSTEMS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLIPORE INVESTMENT HOLDINGS LIMITED;REEL/FRAME:007189/0912

Effective date: 19941102

RR Request for reexamination filed

Effective date: 19940610

FPAY Fee payment

Year of fee payment: 8

CC Certificate of correction
AS Assignment

Owner name: NEXSTAR PHARMACEUTICALS, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERSEPTIVE BIOSYSTEMS, INC.;REEL/FRAME:009097/0853

Effective date: 19980122

AS Assignment

Owner name: PROLIGO L.L.C., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEXSTAR PHARMACEUTICALS, INC.;REEL/FRAME:009436/0625

Effective date: 19980815

FPAY Fee payment

Year of fee payment: 12